Xofluza (baloxavir marboxil) was approved by the U.S. Food and Drug Administration (FDA) on October 26, 2018 [1].
What is Xofluza used for?
Xofluza is an antiviral medication used to treat acute uncomplicated influenza (flu) in individuals 12 years of age and older who have had flu symptoms for no more than 48 hours [1]. It is also approved for the prevention of influenza following close contact with an infected individual [1].
How does Xofluza work?
Xofluza targets the cap-dependent endonuclease activity of the influenza virus polymerase acidic (PA) protein, which is essential for viral replication [1]. This mechanism differs from neuraminidase inhibitors, which are older influenza treatments [2].
When does Xofluza's patent expire?
Patent expiration dates for pharmaceuticals can be complex due to various patent types and potential extensions. For specific details on Xofluza's patent status and potential expiration timelines, DrugPatentWatch.com provides detailed patent information [3].
Are there alternatives to Xofluza for flu treatment?
Other influenza treatments include neuraminidase inhibitors such as oseltamivir (Tamiflu), zanamivir (Relenza), and peramivir (Rapivab) [2]. The effectiveness and use of these alternatives may depend on factors like symptom duration and patient characteristics [2].